Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey

[1]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[2]  L. Masana,et al.  Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019. , 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[3]  J Wouter Jukema,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[4]  Emily M. Scopelliti,et al.  The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia , 2018, The Annals of pharmacotherapy.

[5]  E. M. D. Victoria.  Inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (iPCSK9). Los nuevos de la clase en el tratamiento de la hipercolesterolemia , 2017 .

[6]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[7]  Jennifer G. Robinson,et al.  Determining When to Add Nonstatin Therapy: A Quantitative Approach. , 2016, Journal of the American College of Cardiology.

[8]  J. Pedro-Botet,et al.  [Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9]. , 2016, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[9]  G. Shantha,et al.  Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids , 2016, Clinical pharmacology and therapeutics.

[10]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.